@article{oai:nagoya.repo.nii.ac.jp:00004612,
 author = {Kikkawa, Fumitaka and Nawa, Akihiro and Ino, Kazuhiko and Sibata, Kiyosumi and Kajiyama, Hiroaki and Nomura, Seiji and 吉川, 史隆 and 那波, 明宏 and 柴田, 清住 and 梶山, 広明 and 野村, 誠二},
 issue = {1-2},
 journal = {Nagoya Journal of Medical Science},
 month = {Jan},
 note = {Since most cases of epithelial ovarian cancer are advanced at diagnosis, this disease is one of the most lethal malignancies of the female genital tract. In recent years, aggressive cytoreductive surgery and chemotherapy have been employed in an attempt to improve the survival rate in patients with epithelial ovarian cancer. Introduction of platinum anticancer drugs increased survival rate, and several randomized studies have been tried to establish the better combination of anticancer drugs. As a result, the combination of paclitaxel and carboplatin was considered as standard regimen for the fi rst-line treatment of patients with advanced ovarian cancer. Since International Federation of Gynecology and Obstetrics (FIGO) accepted a postoperative staging system in 1988, staging laparotomy needs hysterectomy, bilateral adnexectomy, omentectomy, and pelvic and para-aorta lymphadenectomy. However, the infl uence of lymphadenectomy on survival still remains controversial. Complete resection of the tumor is often diffi cult since the disease has spread to the abdominal cavity. In such cases, interval debulking surgery is performed after chemotherapy to remove tumors completely. The effectiveness of neoadjuvant chemotherapy and interval debulking surgery still remains unclear. This review will describe the advances in surgical procedures and chemotherapy in treatment of ovarian cancer patients.},
 pages = {19--26},
 title = {Advances in treatment of epithelial ovarian cancer},
 volume = {68},
 year = {2006}
}